



# Chronic Malignancies Working Party CLL & Plasma Cell Disorders

Activities of WP and Subcommittees


Chair: Nicolaus Kröger

Secretary: Stefan Schönland

## Subcommittee Plasma Cell Disorders

Chair: Laurent Garderet, Vice-chair: Stefan Schönland

### Number of MM transplants 2003-2014



## You can help with our Data Quality Initiative

To improve the relapse data quality in MM of the EBMT registry, the CMWP would like to invite you to participate in our Data Quality Initiatives. Queries were made on the database to identify lacking data regarding **relapse and (previous) transplant in MM**. Data Quality Initiatives aim to include more patients with complete data. All future studies would benefit from this DQI i.e. 3<sup>rd</sup> auto-transplant (L. Garderet).

## Expected data request Plasma Cell Leukaemia (April '16)

We need additional information for the primary plasma cell leukaemia:

Confirmation of diagnosis (plasma cell count, plasmacytosis), pre-treatment with novel agent, planned strategy-aim, transplant data (performance status, source, donor, conditioning), and follow-up.


## Myeloma faculty from educational event (Hamburg, Jan '16)




## Outcome of a third salvage ASCT in multiple myeloma

**Goal:** What is the outcome after a 3<sup>rd</sup> ASCT in multiple myeloma? Many patients got a tandem ASCT... and relapse 10 years later! **Patient population:** between 1997-2010; 417 patients with double ASCT Relapse ASCT (AARA), 72 patients with ASCT Relapse ASCT Relapse ASCT (ARARA). **Conclusions:** AARA is a valid option. After the 3<sup>rd</sup> ASCT:  $\geq$  PR=80%; OS=30 months; If interval between 2<sup>nd</sup> ASCT and relapse is more than 3 years, OS=4 years, and PFS=2 years; 4% engraftment failure; NRM=16%.

### Overall survival after 3<sup>rd</sup> auto-SCT



Third ASCT in patients who relapsed after tandem ASCT [AARA] is a valid option.




Longer time interval between 2nd HSCT and relapse is associated with better OS.

## Subcommittee Chronic Lymphocytic Leukemia

Chair: Johannes Schetelig, Vice-Chair: Michel van Gelder

### Number of CLL transplants 2003-2014



## Ibrutinib pre and/or post Allo-HSCT for CLL (NIS)

**Ibrutinib before and/or after Allo-HSCT for Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma:** A joint project of the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL and the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

**Objective** **Pre-transplant exposure:** assess feasibility, safety and efficacy of allo-HSCT after previous ibrutinib exposure **Endpoints** 1-year PFS (*primary*), 1-year NRM, incidence and grade of AGVHD, CIR, time to relapse after allo-HSCT, EFS, OS, time to engraftment

**Objective** **Post-transplant exposure:** assess feasibility, safety and efficacy of ibrutinib administration after a previous allo-HSCT **Endpoints** safety (6-months NRM, *primary*), incidence of grade 2-4 AGVHD, response and duration of response to ibrutinib, incidence or aggravation of CGVHD, OS, prognostic factors for response.

**Result feasibility study** 20 centres from 8 countries already confirmed their participation, expecting to collect a total number of more than 80 patients. Patients included N=22.

	Ibrutinib	Other drugs	Total
CLL	15	3	18
MCL	7	-	7
Other lymphoma	3	2	5

**Principal investigators** CMWP/CLL **Mauricette Michallet** Centre Hospitalier Lyon Sud, France  
CMWP/CLL **Johannes Schetelig** Universitätsklinikum Dresden, Germany  
LWP **Peter Dreger** University Hospital Heidelberg, Germany

## CMWP Business Meeting

EBMT 2016 Valencia

Subcommittees:

PCD and CLL **Monday 4 April, 07:00-09:00 | Room B3 (Level 1, Pav 5)**

MDS and MPN **Tuesday 5 April, 07:00-09:00 | Room 3F**

## Chronic Malignancies Working Party Session

EBMT 2016, Valencia, Tuesday 5 April, 15.45 – 17.15 h | Auditorium 3A

- 1) Welcome and Introduction | Chair: Nicolaus Kröger
- 2) Development of Stem Cell Transplantation for Multiple Myeloma in Europe | Nicolaus Kröger
- 3) Indication for a Single and Tandem autologous Stem Cell Transplantation in 2016 | Michele Cavo
- 4) Optimal Induction, Consolidation and Maintenance before and after auto-SCT in 2016 | Joan Blade
- 5) Salvage Therapy Options after Relapse in 2016 | Laurent Garderet
- 6) Novel agents before and after Stem Cell Transplantation for Myeloma beyond 2016 | Enrique Ocio

## Business Meetings and Educational Events

**CMWP** London/UK, 23 & 24 September 2016

Hosts: V. Potter, D. McLornan, R. Benjamin and K. Raj

## CMWP & CTIWP Educational Event

Come of age... Immunotherapy for Multiple Myeloma

Berlin/Germany, 30 September - 1 October 2016 | [www.csihamburg.de](http://www.csihamburg.de)

## Educational Event

Workshop on Biology, Prevention and Treatment of Relapse after HSCT

Hamburg/Germany, 4 & 5 November 2016 | [www.relapse-after-hsct2016.de](http://www.relapse-after-hsct2016.de)